Prospective multicentre study evaluating ctDNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: NeckTAR-IN protocol
Abstract
Introduction The first therapeutic assessment of locally advanced (LA) head and neck squamous cell carcinomas (HNSCCs) is often performed 10–12 weeks after the end of chemoradiotherapy as a result of the delayed action of radiotherapy. Diagnostic uncertainty between persistent disease and treatment-related changes (oedema, necrosis) can delay confirmation of residual cancer. According to data in the literature, a correlation exists between the detection of circulating tumour DNA (ctDNA) at the end of chemoradiotherapy treatment and residual disease. However, additional data are required before this molecular tool can be used in routine clinical practice. The aim of this clinical trial (NeckTAR-IN) is to assess the usefulness of ctDNA to detect residual disease 3 months after the end of chemoradiotherapy among patients with LA HNSCC. Methods and analysis At M3, objective response (clinical and radiological) will be set against the detection or not of ctDNA in the blood. This is an interventional, multicentre, prospective trial, ancillary to the NeckTAR study. All the patients included in the NeckTAR study are eligible for the NeckTAR-IN study. We expect to enrol 59 patients in this ancillary trial. A blood sample will be taken 1 month and 3 months after the end of chemoradiotherapy. Approval from the ethics committee was granted on 29 August 2025. Ethics and dissemination The study protocol obtained approval from the French Ethics Committee (N°25.02461.000435). The results will be published in scientific journals and presented at conferences. Trial registration number NCT07178847 .
Related
- Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study
- Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
- Incidence of medically attended Lyme borreliosis across endemic regions of six European countries (BOLD): a prospective multicentre active surveillance study
- Explainable computational framework for subtype classification and biomarker identification in head and neck squamous cell carcinoma using machine learning
- Beyond Discrimination: Evaluating Probability Calibration in Radiomics-Image Fusion for Renal Cell Carcinoma Classification
BibTeX
@article{ginzac2026prospective,
title = {{Prospective multicentre study evaluating ctDNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: NeckTAR-IN protocol}},
author = {Angeline Ginzac and Léo Ventelou and Marie-Céleste Ferreira and Laurie Canetti and Julian Biau and Ioana Molnar and Flora Ponelle-Chachuat and Soline Philippe and Nicolas Saroul and Nathalie Pham-Dang and Xavier Durando and Maureen Bernadach},
journal = {BMJ Open},
year = {2026},
month = aug,
doi = {10.1136/bmjopen-2026-118532},
url = {https://hal.science/hal-05735268v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Prospective multicentre study evaluating ctDNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: NeckTAR-IN protocol
AU - Angeline Ginzac
AU - Léo Ventelou
AU - Marie-Céleste Ferreira
AU - Laurie Canetti
AU - Julian Biau
AU - Ioana Molnar
AU - Flora Ponelle-Chachuat
AU - Soline Philippe
AU - Nicolas Saroul
AU - Nathalie Pham-Dang
AU - Xavier Durando
AU - Maureen Bernadach
PY - 2026
DA - 2026/08/07
JO - BMJ Open
DO - 10.1136/bmjopen-2026-118532
UR - https://hal.science/hal-05735268v1
AB - Introduction The first therapeutic assessment of locally advanced (LA) head and neck squamous cell carcinomas (HNSCCs) is often performed 10–12 weeks after the end of chemoradiotherapy as a result of the delayed action of radiotherapy. Diagnostic uncertainty between persistent disease and treatment-related changes (oedema, necrosis) can delay confirmation of residual cancer. According to data in the literature, a correlation exists between the detection of circulating tumour DNA (ctDNA) at the end of chemoradiotherapy treatment and residual disease. However, additional data are required before this molecular tool can be used in routine clinical practice. The aim of this clinical trial (NeckTAR-IN) is to assess the usefulness of ctDNA to detect residual disease 3 months after the end of chemoradiotherapy among patients with LA HNSCC. Methods and analysis At M3, objective response (clinical and radiological) will be set against the detection or not of ctDNA in the blood. This is an interventional, multicentre, prospective trial, ancillary to the NeckTAR study. All the patients included in the NeckTAR study are eligible for the NeckTAR-IN study. We expect to enrol 59 patients in this ancillary trial. A blood sample will be taken 1 month and 3 months after the end of chemoradiotherapy. Approval from the ethics committee was granted on 29 August 2025. Ethics and dissemination The study protocol obtained approval from the French Ethics Committee (N°25.02461.000435). The results will be published in scientific journals and presented at conferences. Trial registration number NCT07178847 .
SN - 2044-6055
ER -